A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation
Latest Information Update: 30 Dec 2023
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 26 Oct 2023 The timeline for the primary end point Overall Response Rate at 168 weeks was changed to 12 weeks.
- 26 Oct 2023 Status changed from active, no longer recruiting to discontinued due to low enrollment.
- 09 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.